Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
$29.39-0.20%
报价 2026-11-06
市值
$167.51B
EV
$223.17B
PE (TTM)
37.3x
预期 PE (FY2026)
9.8x
52 周区间距高点 -4.5%
$23.67$30.79
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-07未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 0.9x | 3.05 → 2.92（1.0x） | 10.1 |
| FY+32028-12 | 0.9x | 3.05 → 2.46（0.8x） | 11.9 |
毛利率 71% · TTM 收入 $63624M · 基数 EPS 3.05（调整后）
电话会信号
辅助标签Q3 20262026-11-03
上调指引
指引 上调
信心 4
分析师 3
“We have line of sight to our aim of delivering a risk adjusted high single digit revenue CAGR from year-end 2028 through year-end 2033.”
原文引用（1）
- 上调指引：we are raising our full-year 2026 revenue guidance by $1.5 billion at the midpoint to a range of $62 billion to $64 billion
蓝色标签在暴涨研究中略有区分度；悬停查看口径。
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| PFEPfizer Inc. | $167.51B | -0.2% | +1.4% | 72.8% | 37.3x | 17.7x | 14.7x | |
| MRKMerck & Co., Inc. | $361.96B | -0.2% | +3.6% | 73.5% | 121.5x | 30.7x | 23.5x | |
| AMGNAmgen Inc. | $248.92B | +0.0% | +4.0% | 70.5% | 24.4x | 12.5x | 30.7x | |
| GILDGilead Sciences, Inc. | $207B | -0.4% | +4.1% | 81.1% | 20.0x | 14.5x | 21.9x | |
| NVONovo Nordisk A/S | $177.74B | +0.0% | – | 78.2% | 10.3x | 7.2x | – | Cheap |
| DHRDanaher Corporation | $161.86B | +1.7% | +3.8% | 60.9% | 37.2x | 21.3x | 30.8x | |
| BMYBristol-Myers Squibb Company PFD CONV 2 | $127.02B | -1.6% | -1.5% | 67.7% | 16.5x | 10.5x | 9.9x | |
| SYKStryker Corporation | $124.02B | -2.8% | +8.8% | 63.5% | 39.2x | 24.7x | 28.9x | |
| SNYSanofi | $113.26B | +0.3% | – | 71.7% | 8.9x | 9.7x | – | |
| 同行中位数 | – | – | +3.9% | 71.1% | 22.2x | 13.5x | 26.2x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-06-28 Q2 2026 | 2026-03-29 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-28 Q3 2025 | 2025-06-29 Q2 2025 | 2025-03-30 Q1 2025 | 2024-12-31 Q4 2024 | 2024-09-29 Q3 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $15.03B | $14.45B | $17.56B | $16.65B | $14.65B | $13.72B | $17.76B | $17.7B |
| Gross Margin | 72.8% | 67.3% | 70% | 74.9% | 64.3% | 71.7% | 73% | 60.8% |
| Operating Margin | 31.3% | 27.9% | 21% | 21.3% | 24.4% | 33.7% | 32.2% | 28.1% |
| Net Income | $-246M | $2.69B | $-1.65B | $3.54B | $2.91B | $2.97B | $403M | $4.47B |
| Diluted EPS | -0.04 | 0.47 | -0.29 | 0.62 | 0.51 | 0.52 | 0.07 | 0.78 |
| Operating Cash Flow | $835M | $2.62B | $5.35B | $4.6B | $-582M | $2.34B | $6.72B | $6.71B |